+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Preferential nuclear accumulation of JAK2V617F in CD34+ but not in granulocytic, megakaryocytic, or erythroid cells of patients with Philadelphia-negative myeloproliferative neoplasia

Blood 116(26): 6023-6026

Preferential nuclear accumulation of JAK2V617F in CD34+ but not in granulocytic, megakaryocytic, or erythroid cells of patients with Philadelphia-negative myeloproliferative neoplasia

Recently, Dawson et al identified a previously unrecognized nuclear role of JAK2 in the phosphorylation of histone H3 in hematopoietic cell lines. We searched nuclear JAK2 in total bone marrow (BM) cells and in 4 sorted BM cell populations (CD34(+), CD15(+), CD41(+), and CD71(+)) of 10 myeloproliferative neoplasia (MPN) patients with JAK2V617F mutation and 5 patients with wild-type JAK2 MPN. Confocal immunofluorescent images and Western blot analyses of nuclear and cytoplasmic fractions found nuclear JAK2 in CD34(+) cells of 10 of 10 JAK2-mutated patients but not in patients with wild-type JAK2. JAK2 was predominantly in the cytoplasmic fraction of differentiated granulocytic, megakaryocytic, or erythroid cells obtained from all patients. JAK2V617F up-regulates LMO2 in K562 and in JAK2V617F-positive CD34(+) cells. The selective JAK2 inhibitor AG490 normalizes the LMO2 levels in V617F-positive K562 and restores the cyto-plasmic localization of JAK2.

Accession: 055116955

PMID: 20861460

DOI: 10.1182/blood-2010-08-302265

Related references

Yonal-Hindilerden, I.; Daglar-Aday, A.; Akadam-Teker, B.; Yilmaz, C.; Nalcaci, M.; Yavuz, A.Selim.; Sargin, D., 2015: Prognostic significance of ASXL1, JAK2V617F mutations and JAK2V617F allele burden in Philadelphia-negative myeloproliferative neoplasms. Despite insights into the genetic basis of Philadelphia-negative myeloproliferative neoplasms (Ph-negative MPNs), a significant proportion of essential thrombocythemia (ET) and primary myelofibrosis (PMF) patients present with no known MPN disease...

Thiele, J.; Kvasnicka, H.Michael.; Diehl, V., 2005: Bone marrow CD34+ progenitor cells in Philadelphia chromosome-negative chronic myeloproliferative disorders--a clinicopathological study on 575 patients. Contrasting the circulating CD34+ hematopoietic progenitor cells (HPCs) in chronic myeloproliferative disorders (CMPDs), scant knowledge is available regarding their quantity in the bone marrow (BM). Therefore, a clinicopathological study was perf...

Arı, M.Cem.; Büyüktaş, D.; Eşkazan, A.Emre.; Ongören Aydın, S.; Tanrıkulu, E.; Başlar, Z.; Buyru, A.Nur.; Ferhanoğlu, B.; Aydın, Yıldız.; Tüzüner, Nükhet.; Soysal, T., 2012: The Association Between JAK2V617F Mutation and Bone Marrow Fibrosis at Diagnosis in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms. <b>Amaç:</b> Kemik iliği fibrozu, Philadelphia negatif miyeloproliferatif neoplazili (MPN) hastalarda morbidite ve mortaliteye yol açan ikinci en sık komplikasyondur. Bu çalışmanın amacı MPN’li hastalarda tanı anında kemik...

Yonal, I.; Pinarbası, B.; Hindilerden, F.; Hancer, V.Sabri.; Nalcaci, M.; Kaymakoglu, S.; Diz-Kucukkaya, R., 2013: The clinical significance of JAK2V617F mutation for Philadelphia-negative chronic myeloproliferative neoplasms in patients with splanchnic vein thrombosis. Polycythemia vera (PV), essential thrombocythemia (ET) and idiopathic myelofibrosis (IMF), collectively known as Philadelphia-negative (Ph-negative) chronic myeloproliferative neoplasms (MPNs), MPNs represent the most common causes of splanchnic v...

Rinaldi, C.R.; Rinaldi, P.; Gemei, M.; Grimaldi, F.; Battipaglia, G.; Del Vecchio, L.; Martino, B.; Specchia, G.; Candoni, A.; Gugliotta, L.; Vannucchi, A.M.; Barbui, T.; Pane, F., 2010: JAK2V617F mutation persists in blasts and mature cells of transformed JAK2V617F-positive-myeloproliferative neoplasia: a European Leukemia Net (ENL) study. American Journal of Hematology 85(5): 383-386

Leutenegger, A.F.; Wüst, W., 1990: Quiz on the topic of infection and surgery. Myeloproliferative syndrome: chronic megakaryocytic granulocytic myelosis with myelofibrosis Philadelphia positive 4/86. Therapeutische Umschau. Revue Therapeutique 47(7): 537-538

Uyanik, M.Sevki.; Baysal, M.; Pamuk, G.Emel.; Maden, M.; Akker, M.; Umit, E.Gulsum.; Demir, M.; Aydogdu, E., 2016: Is JAK2V617F Mutation the Only Factor for Thrombosis in Philadelphia-Negative Chronic Myeloproliferative Neoplasms?. The most common genetic disorder in Philadelphia negative chronic myeloproliferative neoplasms is the JAK2-V617F mutation. In the present study, we aimed to determine risk factors for thrombosis in patients with essential thrombocytosis and polycy...

Padaro, E.; Agbetiafa, K.; Delagnon Kueviakoe, Iénée.Messanh.; Layibo, Y.; Amegbor, K.; Vovor, A.; Giraudier, Séphane.; Sanogo, I.; Segbena, Aé.Yvon., 2013: Myeloproliferative disorders "Philadelphia negative" and JAK2V617F mutation: study of 15 cases in Togo. The goal of our study is to document the prevalence of change JAK2V617F among patients reached of myeloproliferative syndromes (MPS) in Togo in order to evaluate frequencies. This descriptive study included 15 patients followed with the CHU Campus...

Hacibekiroglu, T.; Akinci, S.; Basturk, A.; inal, B.; Guney, T.; Bakanay, S.Mine.; Dilek, I., 2016: Evaluation of Inflammation Parameters in Philadelphia Negative Chronic Myeloproliferative Neoplasia Patients. Chronic myeloproliferative diseases are clonal stem cell diseases which occur as a result of uncontrollable growth and reproduction of hematopoietic stem cells, which are the myeloid series source in bone marrow. Recent studies have suggested that...

Hussein, K.; Dralle, W.; Theophile, K.; Kreipe, H.; Bock, O., 2008: Megakaryocytic expression of miRNA 10a, 17-5p, 20a and 126 in Philadelphia chromosome-negative myeloproliferative neoplasm. Micro RNA (miRNA) are small non-coding RNA molecules which have a post-transcriptional inhibitory regulation function, e.g. in megakaryopoiesis. A characteristic of Philadelphia chromosome-negative myeloproliferative neoplasm (Ph(-) MPN) is the ab...